Securities Class Action Lawsuit Filed Against Alto Neuroscience, Inc.

Strategic Insights -

Investors in Alto Neuroscience, Inc. were notified on August 25, 2025, of a class action securities lawsuit alleging securities fraud. The lawsuit specifically targets investors who purchased Alto common stock in connection with the company's initial public offering on February 2, 2024, or those who acquired Alto securities between February 2, 2024, and October 22, 2024. The filed complaint accuses the defendants of making false statements and concealing that the company's product pipeline, ALTO-100, was less effective in treating major depressive disorder than claimed. This led to an overstatement of the company's business and financial prospects.

Key Takeaways:

  • A class action securities lawsuit has been filed on behalf of investors in Alto Neuroscience, Inc. (NYSE: ANRO) alleging securities fraud.
  • The lawsuit targets investors who purchased Alto common stock in connection with the company's initial public offering on February 2, 2024, or those who acquired Alto securities between February 2, 2024, and October 22, 2024.
  • The complaint alleges that defendants made false statements and concealed that Alto's product pipeline, ALTO-100, was less effective in treating major depressive disorder than claimed.
  • Investors have until September 19, 2025, to request that the Court appoint them as lead plaintiff to share in any recovery.
  • There is no cost or obligation for investors to participate in the lawsuit.
  • Levi & Korsinsky, LLP, a law firm with extensive expertise in securities litigation, is leading the case.
  • The firm has secured hundreds of millions of dollars for aggrieved shareholders and has a track record of winning high-stakes cases.

Statistics:

  • The lawsuit targets investors who acquired Alto securities between February 2, 2024, and October 22, 2024.
  • Case details include allegations that the company's product pipeline was less effective than stated.
  • Investors have until September 19, 2025, to request lead plaintiff status.

Sources:

  • GlobeNewswire: "Levi & Korsinsky, LLP Notifies Investors in Alto Neuroscience, Inc. of Class Action Investigation"
  • Levi & Korsinsky, LLP: Contact Information for Joseph E. Levi and Ed Korsinsky